Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective.
Gérard de PouvourvillePatrick RossignolMeriem BoussahouaJulie ChevalierPeter D GabbRoch PoulnaisDorian VerbouxNaveen RaoElisabeth SörstadiusJuan Jose Garcia SanchezPublished in: Advances in therapy (2023)
In concert with early diagnosis and proactive management of CKD, the expansion of the gliflozin indications into the French CKD population presents the opportunity to reduce the substantial burden associated with cardio-renal complications which outweighs the additional cost of the new treatment. INFOGRAPHIC.